LP-300 is being assessed in never smoker patients with advanced non-small cell lung cancer. Credit: Librepath / commons.wikimedia.org.

Reprocell USA has secured a contract from Lantern Pharma to provide support for a Phase II study of LP-300 for advanced non-small cell lung cancer (NSCLC).

The trial entitled ‘A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers with Advanced Lung Adenocarcinoma (HARMONIC)’ is designed to evaluate LP-300’s effect in combination with standard-of-care chemotherapy on the progression-free and overall survival of never smoker patients with NSCLC.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

In a total of 90 patients, two thirds will receive LP-300 with chemotherapy and a third will receive chemotherapy alone.

The study is planned to be initiated at five clinical trial sites with over 12 locations in the US.

Northwest Oncology, Gabrail Cancer Center, Texas Oncology, Cancer and Blood Specialty Clinic, and New York Cancer and Blood Specialists will be involved in the study.

See Also:

As part of the study, Reprocell will process patient samples and store biomaterial from patients as well as produce Specimen Collection Kits.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In addition, it will archive pathology formalin fixed paraffin embedded samples, and associated H&E-stained slides from selected patients.

Reprocell will also provide cell free DNA isolation from plasma, genomic DNA and/or RNA from the buffy coat fraction.

All pathology materials and biomaterials on-site will be retained by Reprocell until needed for Lantern Pharma.

Reprocell CEO Rama Modali said: “We are pleased to support Lantern Pharma in the Harmonic clinical trial.  We believe that our capabilities in building kits, managing shipments to and from clinical sites and processing the bio samples will help Lantern Pharma in successfully conducting this trial.”